MedTrace Logo

Bivalirudin Infusion for Ventricular Infarction Limitation

NCT02565147 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2018-10-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether the use of bivalirudin will reduce extent of the damage done to the heart muscle in participants who suffered a heart attack, compared to the comparator treatment (heparin).

Conditions

  • Acute Myocardial Infarction

Interventions

PROCEDURE

PPCI

PPCI for treatment of participants presenting with large STEMI.

DRUG

Bivalirudin

Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.

DRUG

Heparin

Heparin is an anticoagulant.

Sponsors & Collaborators

  • The Medicines Company

    lead INDUSTRY

Principal Investigators

  • Robert J Van Geuns, MD · Thorax Centrum, Erasmus Medisch Centrum, s-Grave dijkwal 230, 3015 CE Rotterdam, the Netherlands

  • Ludovic Drouet, MD · Hospital Lariboisiere, Angio-Hematologie, 2 Rue Ambroise Pare, 75475 Paris Cedex 10, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-19
Primary Completion
2016-06-14
Completion
2016-06-14

Countries

  • France
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02565147 on ClinicalTrials.gov